Welcome to LookChem.com Sign In|Join Free

CAS

  • or

140715-61-3

Post Buying Request

140715-61-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

140715-61-3 Usage

Description

CHEMBRDG-BB 5545112, also known as N-(2-amino-3,4-dihydro-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl)thiophene-2-carboxamide, is a synthetic small molecule belonging to the class of pyrrolo[3,2-d]pyrimidine derivatives. It exhibits potential antineoplastic and antineoplastic activities, which are being researched for their therapeutic applications in the treatment of various types of cancers. CHEMBRDG-BB 5545112 may function by inhibiting the activity of certain enzymes that play a role in cancer cell growth and division.

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 5545112 is used as a potential antineoplastic agent for its potential to inhibit the growth and division of cancer cells. It is being researched for its therapeutic applications in the treatment of various types of cancers, making it a promising candidate for the development of new cancer therapies.
Used in Cancer Research:
CHEMBRDG-BB 5545112 is used as a research tool to explore its potential therapeutic applications in the treatment of various types of cancers. Its mechanism of action, which involves inhibiting the activity of certain enzymes involved in cancer cell growth and division, is being studied to better understand its potential as a cancer treatment.
Used in Drug Development:
CHEMBRDG-BB 5545112 is used in the development of new drugs for cancer treatment. Its antineoplastic and antineoplastic activities make it a valuable compound for further research and development, with the potential to contribute to the advancement of cancer therapies.

Check Digit Verification of cas no

The CAS Registry Mumber 140715-61-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,0,7,1 and 5 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 140715-61:
(8*1)+(7*4)+(6*0)+(5*7)+(4*1)+(3*5)+(2*6)+(1*1)=103
103 % 10 = 3
So 140715-61-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H15NO/c1-3-11-8-9-5-4-6-10(7-9)12-2/h4-7,11H,3,8H2,1-2H3

140715-61-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[(3-methoxyphenyl)methyl]ethanamine

1.2 Other means of identification

Product number -
Other names N-ethyl-m-anisylamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:140715-61-3 SDS

140715-61-3Relevant articles and documents

Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors

Yin, Yan,Lin, Li,Ruiz, Claudia,Khan, Susan,Cameron, Michael D.,Grant, Wayne,Pocas, Jennifer,Eid, Nibal,Park, Hajeung,Schr?ter, Thomas,Lograsso, Philip V.,Feng, Yangbo

, p. 3568 - 3581 (2013/06/27)

RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (~7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

Central cholinergic agents. I. Potent acetylcholinesterase inhibitors, 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es, based on a new hypothesis of the enzyme's active site

Ishihara,Kato,Goto

, p. 3225 - 3235 (2007/10/02)

It has been suggested that the active site of acetylcholinesterase contains a hydrophobic binding site (HBS-1), which is closely adjacent to both the anionic and the esteratic sites. In this paper, we assumed that there exists another hydrophobic binding site (HBS-2), some distance removed from the anionic site. On this assumption, a new working hypothesis was proposed for the design of acetylcholinesterase inhibitors. A series of 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es was designed based on this hypothesis and tested for its inhibitory activities on acetylcholinesterase. Some in this series were revealed to be more potent than physostigmine. Optimum activity was found to be associated with a five carbon chain length separating the benzylamino group from the 1H-isoindole-1,3(2H)-dione (phthalimide) moiety. Quantitative study of substitution effect on the phthalimide moiety revealed that hydrophilic and electron-withdrawing groups enhance the activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 140715-61-3